This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The nested case-control study by Dr Blais et al¹ provided some reassurance regarding the safety of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. However, important issues remain unresolved.

In their cohort of older beneficiaries of a health care plan, those treated with HMG-CoA reductase inhibitors were less likely to be diagnosed as having cancer than those treated with bile acid sequestrants. Because the median period of follow-up for the cohort was only 2.7 years, this study does not offer long-term reassurance. Neoplasia from carcinogens can take decades to clinically manifest.² This is not as important in older individuals at high risk for coronary events because neoplasia from the drug might not clinically manifest in their lifetime, whereas protection from coronary events should occur rapidly.³ However, in younger individuals HMG-CoA reductase inhibitors are potentially administered for decades, and there is a possibility for neoplasia from the drug to manifest during their lifetime.

. . . [Full Text of this Article]